Investigation on PD-L1 biology for precise shaping of anticancer adoptive therapies

2019/35/D/NZ6/03073

Keywords

Descriptors

  • NZ6_002: Immunologia kliniczna
  • NZ6_001: Odporność swoista i nieswoista

Panel

NZ6 – Human and animal immunology and infection: immunity, immune disorders, immunotherapy, infectious and invasive diseases, microbiology, transplantology, allergology

Host institution

Instytut Medycyny Doświadczalnej i Klinicznej im. Mirosława Mossakowskiego PAN

Voivodeship: mazowieckie

Other projects carried out by the institution »

Principal investigator (from the host institution)

dr Agnieszka Graczyk-Jarzynka

Number of co-investigators in the project: 4

Call

SONATA 15 – announced on 2019-09-16

Amount awarded
1 624 380 PLN
Project start date
2020-07-08
Project end date
2025-07-07
Project duration
60 months (the same as in the proposal)
Project status
Project completed

Project description

Download the project description in a pdf file

Note — project descriptions were prepared by the authors of the applications themselves and placed in the system in an unchanged form.

Information in the final report

Publication in academic press/journals (1)

  1. PD-L1 CAR effector cells induce self-amplifying cytotoxic effects against target cells.

    Authors:
    Malgorzata Bajor, Agnieszka Graczyk-Jarzynka, Katsiaryna Marhelava, Anna Burdzinska, Angelika Muchowicz, Agnieszka Goral, Andriy Zhylko, Karolina Soroczynska, Kuba Retecki, Marta Krawczyk, Marta Klopotowska, Zofia Pilch, Leszek Paczek, Karl-Johan Malmberg, Sébastien Wälchli, Magdalena Winiarska Radoslaw Zagozdzon
    Academic press:
    Journal for ImmunoTherapy of Cancer (year: 2022, volume: 10(1):e002500, pages: 39), Publisher: BMJ journals
    Status:
    Published
    DOI:
    10.1136/jitc-2021-002500 – link to the publication

« New search

Graphic design and implementation: Jakub Piotrowski